Compare EVO & CDNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EVO | CDNA |
|---|---|---|
| Founded | 1993 | 1998 |
| Country | Germany | United States |
| Employees | 4553 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 934.1M | 1.1B |
| IPO Year | N/A | 2007 |
| Metric | EVO | CDNA |
|---|---|---|
| Price | $3.01 | $21.74 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 6 |
| Target Price | $7.00 | ★ $28.00 |
| AVG Volume (30 Days) | 85.0K | ★ 652.5K |
| Earning Date | 04-08-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.05 |
| Revenue | N/A | ★ $48,324,000.00 |
| Revenue This Year | $1.37 | $16.01 |
| Revenue Next Year | $10.05 | $11.31 |
| P/E Ratio | ★ N/A | $429.80 |
| Revenue Growth | N/A | ★ 18.93 |
| 52 Week Low | $2.31 | $10.96 |
| 52 Week High | $4.48 | $23.24 |
| Indicator | EVO | CDNA |
|---|---|---|
| Relative Strength Index (RSI) | 53.04 | 59.06 |
| Support Level | $2.88 | $15.80 |
| Resistance Level | $3.36 | $22.89 |
| Average True Range (ATR) | 0.09 | 1.00 |
| MACD | -0.01 | -0.06 |
| Stochastic Oscillator | 54.34 | 76.54 |
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically it generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.